Informations générales (source: ClinicalTrials.gov)
Influence of Olfaction Essential Oils on the Consumption of Benzodiazepine Receptor Agonists & Z-Drugs (BZRAs) Prescribed as " if Needed " in Psychiatric Outpatients (HECBA-PSY). (HECBA-PSY)
Interventional
Phase 4
Etablissement Public de Santé Barthélemy Durand (Voir sur ClinicalTrials)
avril 2021
juillet 2023
05 octobre 2024
The goal of this interventional study is to test the use of olfactory Essential Oils
through a nasal stick as one of the non-medicinal strategies to propose to the patient to
reduce the consumption of medication in a population of stabilized patients with
psychiatric disorder.
The main objective is to evaluate whether the olfaction of a mixture of essential oils
can reduce the intake of BZRAs, prescribed if needed.
The investigators want to compare the number of medications prescribed on "if needed"
basis before and after the introduction of Essential Oils.
A period prior to inclusion is used to assess the participant's frequency of BZRA use.
Then, participants will received Essential Oils through a nasal stick during 4 weeks.
During this period, the patient completes weekly anxiety and sleep scales and at the
final visit, weekly and monthly anxiety and sleep scales.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| EPS BARTHELEMY DURAND | Adelaide Aduayi | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Adult without legal protection measures
- Ambulatory followed up
- Stabilised main psychiatric pathology
- Patient having had recourse between 3 and 21 times a week in the previous 14 days to
a benzodiazepine or related treatment, for anxiolytic or hypnotic purposes,
prescribed "if necessary" (on request)
- Patient who understand French both orally and in writing
- Patient who do not have an identified organic cause for their disorder
- Patient who be affiliated to a social security scheme
- Patient who have given their free and informed consent and signed the consent form
- Adult without legal protection measures
- Ambulatory followed up
- Stabilised main psychiatric pathology
- Patient having had recourse between 3 and 21 times a week in the previous 14 days to
a benzodiazepine or related treatment, for anxiolytic or hypnotic purposes,
prescribed "if necessary" (on request)
- Patient who understand French both orally and in writing
- Patient who do not have an identified organic cause for their disorder
- Patient who be affiliated to a social security scheme
- Patient who have given their free and informed consent and signed the consent form
- Patients with asthma or unstable epilepsy
- Pregnancy or breastfeeding
- EO allergies
- Patients having already a regular consumption of EO for the study indication
- Patients under guardianship or under reinforced guardianship